Tag: clinical development strategy

Talent, Skills and Operating Models Needed to Deliver on Rare/Ultra-Rare Development Models Talent, Skills and Operating Models Needed to Deliver on Rare/Ultra-Rare Development Models In the complex landscape of pharmaceutical research and development (R&D), the emergence of rare and ultra-rare diseases presents unique challenges and opportunities. As a consequence, clinical operations, regulatory affairs, medical affairs,…

Read More “Talent, Skills and Operating Models Needed to Deliver on Rare/Ultra-Rare Development Models” »

Using Real-World Data and RWE to Strengthen Rare/Ultra-Rare Development Models Decisions The development of innovative therapies for rare and ultra-rare diseases presents unique challenges within the pharmaceutical landscape. Efficacious decision-making in this area necessitates a robust understanding of both clinical and real-world data (RWD). This comprehensive tutorial aims to provide clinical operations, regulatory affairs, medical…

Read More “Using Real-World Data and RWE to Strengthen Rare/Ultra-Rare Development Models Decisions” »

Scenario Planning and Portfolio Strategy Anchored in Rare/Ultra-Rare Development Models Understanding Rare and Ultra-Rare Diseases in Clinical Trials The landscape of clinical trials is continuously evolving, particularly in the domain of rare and ultra-rare diseases. Rare diseases are defined by the European Medicines Agency (EMA) as conditions affecting fewer than 5 in 10,000 people in…

Read More “Scenario Planning and Portfolio Strategy Anchored in Rare/Ultra-Rare Development Models” »

Digital Tools, Platforms and Data Lakes to Power Rare/Ultra-Rare Development Models The landscape of pharmaceutical research and development, particularly for rare and ultra-rare conditions, is increasingly reliant on digital tools, platforms, and data lakes. This comprehensive tutorial will provide insights into leveraging these technological advancements to enhance pharmacovigilance in clinical trials and streamline the processes…

Read More “Digital Tools, Platforms and Data Lakes to Power Rare/Ultra-Rare Development Models” »

KPIs, Dashboards and Analytics to Measure Rare/Ultra-Rare Development Models Success KPIs, Dashboards and Analytics to Measure Rare/Ultra-Rare Development Models Success In an increasingly complex pharmaceutical landscape, the development of treatments for rare and ultra-rare diseases holds significance yet poses unique challenges. The ability to measure success through robust analytics and appropriate Key Performance Indicators (KPIs)…

Read More “KPIs, Dashboards and Analytics to Measure Rare/Ultra-Rare Development Models Success” »

Global Regulatory Expectations Shaping Rare/Ultra-Rare Development Models in the US, EU and UK In recent years, the landscape of pharmaceutical development, particularly concerning rare and ultra-rare diseases, has witnessed transformative changes. Regulatory agencies in the US, EU, and UK have adapted their frameworks to facilitate the development of innovative therapies targeting these sectors. This article…

Read More “Global Regulatory Expectations Shaping Rare/Ultra-Rare Development Models in the US, EU and UK” »

Partnering, Outsourcing and Alliances to Scale Rare/Ultra-Rare Development Models The development of therapies for rare and ultra-rare diseases presents unique challenges and opportunities within the pharmaceutical research and development (R&D) landscape. As clinical operations, regulatory affairs, medical affairs, and R&D professionals brace themselves against these challenges, effective partnerships, outsourcing strategies, and collaborative alliances emerge as…

Read More “Partnering, Outsourcing and Alliances to Scale Rare/Ultra-Rare Development Models” »

Common Pitfalls in Rare/Ultra-Rare Development Models—and How to Avoid Costly Rework Introduction to Rare and Ultra-Rare Disease Models In the field of pharmaceutical R&D, the development of treatments for rare and ultra-rare diseases presents unique challenges and opportunities. Rare diseases affect fewer than 200,000 individuals in the United States, while ultra-rare diseases impact an even…

Read More “Common Pitfalls in Rare/Ultra-Rare Development Models—and How to Avoid Costly Rework” »

Rare/Ultra-Rare Development Models: Strategic Playbook for Modern Pharma R&D Rare/Ultra-Rare Development Models: Strategic Playbook for Modern Pharma R&D Introduction to Rare and Ultra-Rare Diseases Rare and ultra-rare diseases present unique challenges in pharmaceutical research and development (R&D). Defined as conditions affecting a small percentage of the population, their lack of prevalence often leads to heightened…

Read More “Rare/Ultra-Rare Development Models: Strategic Playbook for Modern Pharma R&D” »

How to Design Rare/Ultra-Rare Development Models That Accelerates Time-to-Proof-of-Concept How to Design Rare/Ultra-Rare Development Models That Accelerates Time-to-Proof-of-Concept The rise of precision medicine and individualized treatment has brought forth new challenges and opportunities in the pharmaceutical industry, particularly in the context of rare and ultra-rare diseases. In designing and analyzing clinical trials for these conditions,…

Read More “How to Design Rare/Ultra-Rare Development Models That Accelerates Time-to-Proof-of-Concept” »